Cogent Biosciences, Inc.
COGT
Pozycja w akcjach
#3334
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Cena akcji
$30.11
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$5.22B
Zmiana (1 dzień)
2.00%
Zmiana (1 rok)
85.64%
Kraj
US
Handel Cogent Biosciences, Inc. (COGT)
Kategoria
Healthcare
Zyski dla Cogent Biosciences, Inc. (COGT)
Zyski w Jun 2026 TTM: $-377.18M
Według najnowszych raportów finansowych Cogent Biosciences, Inc., obecny zysk firmy wynosi $-377.18M. W roku 2023 firma osiągnęła zysk w wysokości $-192.41M, spadek w porównaniu do zysku z roku 2022, który wynosił $-140.24M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Cogent Biosciences, Inc. od 2015 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $-377.18M | 47.42% |
| 2024 | $-255.86M | 32.98% |
| 2023 | $-192.41M | 37.20% |
| 2022 | $-140.24M | 94.04% |
| 2021 | $-72.27M | -3.39% |
| 2020 | $-74.81M | 135.00% |
| 2019 | $-31.83M | -7.82% |
| 2018 | $-34.53M | 35.46% |
| 2017 | $-25.49M | 40.65% |
| 2016 | $-18.12M | 174.94% |
| 2015 | $-6.59M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | -1,498.51% |
US
|
|
| $-3.09B | 718.44% |
US
|
|
| $-4.02B | 964.80% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -617.17% |
NL
|
